Overall, given its function in TNF- and TLR-mediated inflammation, Sam68 may prove a potential therapeutic target for the treatment of UC and potentially IBD with fewer side effects than the global TNF inhibition currently recommended in the clinic for IBD. The gene discussed is KHDRBS1; the disease is inflammatory bowel disease.